@article{oai:niigata-u.repo.nii.ac.jp:00018847,
 author = {櫻川, 信男},
 issue = {12},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Dec},
 note = {The author reported the works on Regulation mechanism of thrombosis and hemostasis with works of antithrombim III which were performed for last 16 years in his laboratory. a) Antithrombim III abnormality Toyama (Type IIb)：One point mutation (^<47>Arg→Cys) which invited the loss of heparin binding activity was found to be homogeneous with occurrence of cerebral thrombosis, and the first case in the world. b) Antithrombin III abnormality Aomori (Type IIa)：One point mutation (＾<393>Arg→His) which invited the loss of thrombin binding activity was found to be heterogeneous with occurrence of cerebral thrombosis, and the first case in Japan. c) Antithrombin III abnormality (Type I) with normal delivery with admintstration of antithrombin III concentrates and low molecular weight heparin preparations. d) Antithrombin III producing hepatocyte cell carcinoma：Antithrombin III level was increased to be 122 mg/dl (540 % compared with normal value) with normal biological function. Pathohistological finding was Edmondson I, and reported as the first case in the world. e) Interaction between antithrombin III and heparin cofactir II. f) Interaction between antithrombin III and endothelial cells which showed defensive features with the stimuli of thrombin from the points of thrombotic and hemostatic views. h) Novel antithrombotic drugs：Low molecular weight heparin preparation was administered to treat thrombosis. The traditional herbal medicines were studied experimentally to treat thrombosis.},
 pages = {859--872},
 title = {アンチトロンビンIIIを中心とした血栓止血の制御機構},
 volume = {108},
 year = {1994}
}